Derivatives of C2-substituted indan-1-ol systems for the prophylaxis or treatment of obesity

US6667345B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Gerhard Jaehne · Frankfurt, DE
• Volker Krone · Flörsheim, DE
• Martin Bickel · Frankfurt am Main, DE
• Matthias Gossel · Frankfurt am Main, DE

Key dates

• Filing date: Aug 29, 2002
• Grant date: Dec 23, 2003
• Expiry date: Aug 29, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P3/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Derivatives of C2-substituted indan-1-ol compounds of the formula I: its physiologically acceptable salts, and its physiologically functional derivatives for the prophylaxis or treatment of obesity are disclosed herein. Compositions comprising the same, methods for preparing the instant compounds, and methods for reducing weight in mammals and for the prophylaxis or treatment of obesity are also described.